In spite of recent advances, cancer remains a leading cause of death in the United States, and there is an urgent need for new therapies. Genome-wide studies of hundreds of human tumors have revealed pre-mRNA splicing as a critical pathway for cancer cell growth, and thus an attractive target for new therapies. Many of the proteins involved with pre-mRNA splicing lack enzymatic activity, and therefore are unusually difficult to target with small molecule drugs. We have recently discovered a class of anticancer sulfonamides that target pre-mRNA splicing which we refer to as SPLAMs (SPLicing inhibitor sulfonAMides). SPLAMs act by recruiting RBM39 (RNA binding motif 39) as a neo-substrate to DCAF15 (DDB1/CUL Associated Factor 15). DCAF15 is part of a CUL4 E3 ubiquitin ligase receptor complex. As a consequence, recruitment of RBM39 to DCAF15 leads to RBM39 ubiquitination and proteasomal degradation. RBM39 is important for pre-mRNA splicing of select introns and exons. Therefore, as a consequence of SPLAM treatment, RBM39 degradation leads to pre-mRNA splicing defects. The mechanism of action of SPLAMs is similar to the FDA approved drugs, thalidomide and lenalidomide (also known as IMiDs). IMiDs recruit neo- substrates to cereblon, which is another member of the DCAF family of proteins. IMiD binding to CRBN has pleiotropic effects which are either the result of targeting unique neo-substrates or inhibiting the endogenous activity of cereblon. Currently, it is not known as to what effects SPLAM binding to DCAF15 has on alternative neo-substrates and endogenous activity. In our first aim, we propose to identify a DCAF15 mutation that is resistant to SPLAMs in order to identify on-target cellular pathways influenced by SPLAMs. In our second aim, we propose a set of experiments to identify both DCAF15 endogenous substrates as well as neo-substrates other than RBM39. The clinical development of a SPLAM based therapy will require identifying which patients are most likely to respond. We have found that RBM39 degradation only causes cell death in a subset of cancer cells. In our final aim, we propose a set of experiments to understand the basis for this selectivity by studying the function of RBM39 in SPLAM-sensitive and insensitive cells. In particular, our preliminary data suggests that cancer cells with mutations in splicing factors that are also found in human cancers are sensitive to SPLAMs. We propose a set of experiments to study RBM39 biology and SPLAM sensitivity in models of human cancer harboring these splicing mutations.

Public Health Relevance

There are no approved drugs targeting pre-mRNA splicing in cancer. We have discovered a new class of small molecule drugs that target pre-mRNA splicing. Our proposed studies, which aim to understand their mechanism of action, will catalyze their development into a new class of cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
3R37CA226771-03S1
Application #
10150692
Study Section
Program Officer
Venkatachalam, Sundaresan
Project Start
2020-05-01
Project End
2023-02-28
Budget Start
2020-09-01
Budget End
2021-02-28
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390